News
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent
News
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
Stem Cell Therapeutics Corp. announces that it has been granted U.S. Patent 7,704,737 entitled, "Oligodendrocyte Production from Multipotent Neural Stem Cells".
The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows: "The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."
The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows: "The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."
Advertisement
